Nordic Nanovector ASA notes that promising results from its preclinical research collaboration to develop a novel CD37-targeting alpha therapy for B-cell tumours have been reported in an oral presentation at TAT11, the 11th International Symposium on Targeted-Alpha-Therapy.
OSLO, Norway, April 2, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) notes that promising results from its preclinical research collaboration to develop a novel CD37-targeting alpha therapy for B-cell tumours have been reported today in an oral presentation at TAT11, the 11th International Symposium on Targeted-Alpha-Therapy (1-4 April, Ottawa, Canada).
The research collaboration with Orano Med (formerly known as AREVA Med) was established in June 2016 to develop and investigate a next-generation targeted alpha therapy comprising Nordic Nanovector’s chimeric anti-CD37 antibody (NNV003) and the alpha-particle-generator lead-212 (212Pb) for the treatment of B-cell malignancies.
The results reported in an oral presentation given today describe promising findings from preclinical studies investigating the tolerability and dose-dependent efficacy of 212Pb-NNV003 in mouse models of chronic lymphocytic leukaemia (CLL) and Burkitt’s lymphoma (a type of non-Hodgkin’s lymphoma, NHL).
In the studies, 212Pb-NNV003 displayed a favourable toxicity profile after a single intravenous injection. In one study, 100% of mice with tumour xenografts were alive five months after the injection of 212Pb-NNV003, while only 50% of control mice receiving cold antibody where alive after 1.5 months.
Jostein Dahle, Chief Scientific Officer of Nordic Nanovector, said: “Our research collaboration with Orano Med continues to produce promising preclinical results and provides an early demonstration of the potential of 212Pb-conjugated CD37-targeted alpha therapy to treat leukaemias and lymphomas where there is no substantial tumour mass and tumour cells are near healthy tissues. This approach also may prove useful for CLL and NHL patients who have relapsed or become refractory to standard CD20-targeting agents that are used in front-line therapy. We look forward to further results from this research programme.”
The oral presentation entitled 212Pb-NNV003 as a Novel Targeted Alpha Therapy for CD37 Positive B-cell Chronic Lymphocytic Leukaemia (CLL) and Non-Hodgkin’s Lymphoma (NHL) was given by Dr A. Saidi of Orano Med.
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.
Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.
Further information can be found at www.nordicnanovector.com
Forward-looking statements
This press release contains certain forward-looking statements. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector’s business, financial condition and results of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “targets”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. These forward-looking statements are not historic facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector’s strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector’s product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector’s potential market and industry, Nordic Nanovector’s freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.
For further information, please contact:
IR enquiries
Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com
International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: nordicnanovector@citigatedewerogerson.com
This information was brought to you by Cision http://news.cision.com
View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-promising-results-from-preclinical-studies-with-a-novel-cd37-targeted-alpha-therapy-for-b-cell-tumours-presented-at-tat11-300822527.html
SOURCE Nordic Nanovector
Company Codes: Bloomberg:NANO@NO, ISIN:NO0010597883, Oslo:NANO, RICS:NANO.OL, Stockholm:NANO
